» Articles » PMID: 35214911

Nanomaterial Probes for Nuclear Imaging

Overview
Date 2022 Feb 26
PMID 35214911
Authors
Affiliations
Soon will be listed here.
Abstract

Nuclear imaging is a powerful non-invasive imaging technique that is rapidly developing in medical theranostics. Nuclear imaging requires radiolabeling isotopes for non-invasive imaging through the radioactive decay emission of the radionuclide. Nuclear imaging probes, commonly known as radiotracers, are radioisotope-labeled small molecules. Nanomaterials have shown potential as nuclear imaging probes for theranostic applications. By modifying the surface of nanomaterials, multifunctional radio-labeled nanomaterials can be obtained for in vivo biodistribution and targeting in initial animal imaging studies. Various surface modification strategies have been developed, and targeting moieties have been attached to the nanomaterials to render biocompatibility and enable specific targeting. Through integration of complementary imaging probes to a single nanoparticulate, multimodal molecular imaging can be performed as images with high sensitivity, resolution, and specificity. In this review, nanomaterial nuclear imaging probes including inorganic nanomaterials such as quantum dots (QDs), organic nanomaterials such as liposomes, and exosomes are summarized. These new developments in nanomaterials are expected to introduce a paradigm shift in nuclear imaging, thereby creating new opportunities for theranostic medical imaging tools.

Citing Articles

Application of rare earth elements in dual-modality molecular probes.

He J, Yang W, Quan W, Yang Y, Zhang Z, Luo Q RSC Adv. 2024; 14(52):38480-38490.

PMID: 39640527 PMC: 11618533. DOI: 10.1039/d4ra04987j.


Theranostics with photodynamic therapy for personalized medicine: to see and to treat.

Wang Y, Staudinger J, Mindt T, Gasser G Theranostics. 2023; 13(15):5501-5544.

PMID: 37908729 PMC: 10614685. DOI: 10.7150/thno.87363.


Exploring the Potential of Nanogels: From Drug Carriers to Radiopharmaceutical Agents.

Kubeil M, Suzuki Y, Casulli M, Kamal R, Hashimoto T, Bachmann M Adv Healthc Mater. 2023; 13(1):e2301404.

PMID: 37717209 PMC: 11468994. DOI: 10.1002/adhm.202301404.


Development of a Radiolabeled Folate-Mediated Drug Delivery System for Effective Delivery of Docetaxel.

Cetin O, Gungor B, Ichedef C, Parlak Y, Bilgin E, Ustun F ACS Omega. 2023; 8(28):25316-25325.

PMID: 37483227 PMC: 10357535. DOI: 10.1021/acsomega.3c02656.


Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review.

Mdanda S, Ngema L, Mdlophane A, Sathekge M, Zeevaart J Pharmaceutics. 2023; 15(6).

PMID: 37376167 PMC: 10304099. DOI: 10.3390/pharmaceutics15061719.


References
1.
Pretze M, van der Meulen N, Wangler C, Schibli R, Wangler B . Targeted Cu-labeled gold nanoparticles for dual imaging with positron emission tomography and optical imaging. J Labelled Comp Radiopharm. 2019; 62(8):471-482. DOI: 10.1002/jlcr.3736. View

2.
Zahavi D, Weiner L . Monoclonal Antibodies in Cancer Therapy. Antibodies (Basel). 2020; 9(3). PMC: 7551545. DOI: 10.3390/antib9030034. View

3.
de Sa A, Prata M, Geraldes C, Andre J . Triaza-based amphiphilic chelators: synthetic route, in vitro characterization and in vivo studies of their Ga(III) and Al(III) chelates. J Inorg Biochem. 2010; 104(10):1051-62. DOI: 10.1016/j.jinorgbio.2010.06.002. View

4.
Fayez H, El-Motaleb M, Selim A . Synergistic Cytotoxicity Of Shikonin-Silver Nanoparticles As An Opportunity For Lung Cancer. J Labelled Comp Radiopharm. 2019; 63(1):25-32. DOI: 10.1002/jlcr.3818. View

5.
Almeida S, Santos L, Falcao A, Gomes C, Abrunhosa A . In Vivo Tracking of Extracellular Vesicles by Nuclear Imaging: Advances in Radiolabeling Strategies. Int J Mol Sci. 2020; 21(24). PMC: 7764519. DOI: 10.3390/ijms21249443. View